Pepinemab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pepinemab
Accession Number
DB15155
Description

Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).

Type
Biotech
Groups
Investigational
Synonyms
  • MOAB VX15/2503
  • VX15/2503

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
BPZ4A29SYE
CAS number
2097151-87-4

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentHuntington's Disease (HD)1
1CompletedTreatmentDisseminated Sclerosis1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentPathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v81
1RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentRecurrent Malignant Solid Neoplasm / Recurrent Osteosarcoma / Refractory Malignant Solid Neoplasm / Refractory Osteosarcoma1
1, 2Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
1, 2Not Yet RecruitingTreatmentRecurrent Malignant Solid Neoplasm / Recurrent Osteosarcoma / Refractory Malignant Solid Neoplasm1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:54 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates